[In vitro susceptibility to fluconazole of fungal strains freshly isolated from child patients with deep-seated mycoses]
- PMID: 8230734
[In vitro susceptibility to fluconazole of fungal strains freshly isolated from child patients with deep-seated mycoses]
Abstract
The susceptibility to fluconazole (FLCZ) were evaluated for 40 strains of 8 yeast species and 4 strains of 3 Aspergillus species, all of which were isolated from clinical specimens during clinical trials of FLCZ in child patients performed from January 1991 to January 1993 in this country. The in vitro activity of FLCZ against yeast isolates and Aspergillus isolates were measured using the microdilution method with semisolid SAAMF (synthetic amino acid medium fungal) agar and the macrodilution method with Eagle MEM (minimum essential medium), respectively, using amphotericin B (AMPH) and flucytosine as the reference drugs. Out of all yeast species tested, Candida albicans and Candida tropicalis were the most susceptible to FLCZ with geometric mean (GM)-MICs of < 0.4 microgram/ml that were far less than the corresponding values for AMPH or flucytosine. On the other hand, FLCZ showed the lowest activity against Candida krusei and Candida glabrata with GM-MICs of approximately 10 micrograms/ml that were slightly higher than those for AMPH. The susceptibilities to FLCZ of Candida parapsilosis, Candida pelliculosa (anamorph of Hansenula anomala), Candida famata, and Trichosporon cutaneum were intermediate. Antifungal activities of FLCZ and the 2 reference drugs against aspergilli were determined on the basis of the amount of total protein recovered from drug-treated cultures relative to that from drug-free control cultures. Fifty percent and 90% inhibitory concentrations of FLCZ against 2 isolates of Aspergillus fumigatus were 6.25-25 micrograms/ml and 50 micrograms/ml, respectively. Against this and 2 other species of Aspergillus, AMPH appeared more highly active than FLCZ.
Similar articles
-
In vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012.Mycoses. 2015 Apr;58(4):209-14. doi: 10.1111/myc.12299. Epub 2015 Feb 27. Mycoses. 2015. PMID: 25727853
-
[The in vitro antifungal activities of fluconazole against pathogenic yeasts recently isolated from clinical specimens].Jpn J Antibiot. 1997 Sep;50(9):799-805. Jpn J Antibiot. 1997. PMID: 9394240 Japanese.
-
Candida and candidaemia. Susceptibility and epidemiology.Dan Med J. 2013 Nov;60(11):B4698. Dan Med J. 2013. PMID: 24192246 Review.
-
[In vitro activity of a new semisynthetic echinocandin, micafungin, against clinical isolates of Candida species isolated in Tenri Hospital].Jpn J Antibiot. 2003 Dec;56(6):705-11. Jpn J Antibiot. 2003. PMID: 15007879 Japanese.
-
Antifungal drug resistance in pathogenic fungi.Med Mycol. 1998;36 Suppl 1:119-28. Med Mycol. 1998. PMID: 9988500 Review.
Cited by
-
New and emerging yeast pathogens.Clin Microbiol Rev. 1995 Oct;8(4):462-78. doi: 10.1128/CMR.8.4.462. Clin Microbiol Rev. 1995. PMID: 8665465 Free PMC article. Review.
-
Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.Drugs. 1995 Oct;50(4):658-90. doi: 10.2165/00003495-199550040-00007. Drugs. 1995. PMID: 8536553 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical